Anzeige
Mehr »
Dienstag, 01.07.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
38 Leser
Artikel bewerten:
(0)

Fetal Bovine Serum Market to Reach $1.03 Bn, Globally, by 2025 at 5.1% CAGR: Allied Market Research

PORTLAND, Oregon, May 9, 2019 /PRNewswire/ -- Allied Market Research published a report, titled, "Fetal Bovine Serum Market by Application (Biopharmaceuticals, Cell Culture, Human & Animal Vaccine Production, and Others) and End User (Biotechnology & Pharmaceutical Company, Academic Institute, and Research Laboratory): Global Opportunity Analysis and Industry Forecast, 2018-2025." According to the report, the global fetal bovine serum market garnered $695 million in 2017, and is expected to generate $1.03 billion by 2025, registering a CAGR of 5.1 % from 2018 to 2025.

Allied_Market_Research_Logo

Increase in R&D activities for producing novel biopharmaceuticals along with the expansion of biopharmaceutical industry drives the global fetal bovine serum market growth. Moreover, rise in investments and funding for research activities in developed and developing countries supplement the market growth. However, ethical & scientific issues related to the misuse of biotechnology research practices and scarcity of skilled personnel hinder the growth in the market. Contrarily, untapped potential in emerging geographies would offer new opportunities in the near future.

Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/5261

Cell culture segment to continue its leadership in terms of revenue by 2025

Based on application, the cell culture segment contributed for nearly two-fifths of the total market share, and is estimated to continue its leadership in terms of revenue during the forecast period. This is due to surge in government funding and increase in R&D activities. However, the biopharmaceuticals segment is expected to grow at the highest CAGR of 5.9% from 2018 to 2025, owing to rise in biotechnology research for the development of human & animal vaccines.

Biotechnology and pharmaceutical company segment to be lucrative

Based on end user, the biotechnology and pharmaceutical company segment accounted for nearly half of the total market share in 2017, and is expected to maintain its dominance during the forecast period. Moreover, it is expected to register the highest growth rate, with a CAGR of 5.5% from 2018 to 2025. It is a lucrative segment, owing to increase in research activities related to biotechnology by the key players along with rise in small scale players. The research also analyzes academic institutes and research institutes.

North America to its dominance in terms of revenue by 2025

North America accounted for more than two-fifths of the total market share in 2017, and will maintain its dominance in terms of revenue by 2025. This is due to the well-established companies related to biotechnology research and presence of well-equipped research laboratories. On the other hand, Asia-Pacific is estimated to grow at the largest CAGR of 6.3% during the forecast period. This is attributed to penetration of leading biotech companies including Bio-Rad, Thermo Fischer, and others in the region and surge in government initiatives for biotech research.

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/5261

Frontrunners of the industry

Leading market players analyzed in the research include GE Healthcare, HiMedia Laboratories Pvt., Ltd., Merck KGaA (Sigma Aldrich), Biowest, Bio-Techne, Atlas Biologicals, Biological Industries, PAN-Biotech, Rocky Mountain Biologicals, and Thermo Fisher Scientific Inc.

Access KNOWLEDGE TREE (Premium on-demand, subscription-based pricing model) at:https://www.alliedmarketresearch.com/knowledgetree

Knowledge tree is a cloud-based intelligence platform that offers more than 2,000 selective, off-the-shelf reports on niche markets to enable our clients gain deep insights on the latest trends, dynamic technologies, and emerging application areas.

Similar Reports:

Animal Vaccines Market - Global Opportunity Analysis and Industry Forecast, 2018 - 2025

Biotechnology Media, Sera and Reagents Market - Global Opportunity Analysis and Industry Forecast, 2018 - 2025

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

Logo: https://mma.prnewswire.com/media/636519/Allied_Market_Research_Logo.jpg

© 2019 PR Newswire
Die USA haben fertig! 5 Aktien für den China-Boom
Die Finanzwelt ist im Umbruch! Nach Jahren der Dominanz erschüttert Donald Trumps erratische Wirtschaftspolitik das Fundament des amerikanischen Kapitalismus. Handelskriege, Rekordzölle und politische Isolation haben eine Kapitalflucht historischen Ausmaßes ausgelöst.

Milliarden strömen aus den USA – und suchen neue, lukrative Ziele. Und genau hier kommt China ins Spiel. Trotz aller Spannungen wächst die chinesische Wirtschaft dynamisch weiter, Innovation und Digitalisierung treiben die Märkte an.

Im kostenlosen Spezialreport stellen wir Ihnen 5 Aktien aus China vor, die vom US-Niedergang profitieren und das Potenzial haben, den Markt regelrecht zu überflügeln. Wer jetzt klug investiert, sichert sich den Zugang zu den neuen Wachstums-Champions von morgen.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche 5 Aktien die Konkurrenz aus den USA outperformen dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.